Scott Antonia

Positions:

Professor of Medicine

Medicine, Medical Oncology
School of Medicine

Member of the Duke Cancer Institute

Duke Cancer Institute
School of Medicine

Education:

Ph.D. 1987

University of Connecticut School of Medicine

M.D. 1989

University of Connecticut School of Medicine

Internal Medicine Residency

Yale University School of Medicine

Medical Oncology Fellowship

Yale University School of Medicine

Postdoctoral Fellowship, Immunobiology

Yale University School of Medicine

Grants:

PIVOT-02

Administered By
Duke Cancer Institute
Role
Principal Investigator
Start Date
End Date

Eco-Evolutionary dynamics of NSCLC to immunotherapy: Response and Resistance

Administered By
Medicine, Medical Oncology
Role
Principal Investigator
Start Date
End Date

Targeting Immunosuppressive Cancer Associated Fibroblasts and Immune Checkpoints in NSCLC

Administered By
Medicine, Medical Oncology
Role
Principal Investigator
Start Date
End Date

Eco-Evolutionary dynamics of NSCLC to immunotherapy: Response and Resistance

Administered By
Medicine, Medical Oncology
Role
Principal Investigator
Start Date
End Date

Tumor Infiltrating lymphocyte adoptive T cell therapy for NSCLC

Administered By
Medicine, Medical Oncology
Role
Principal Investigator
Start Date
End Date

Publications:

Four-year survival with nivolumab in patients with previously treated advanced non-small-cell lung cancer: a pooled analysis.

BACKGROUND: Phase 3 clinical data has shown higher proportions of patients with objective response, longer response duration, and longer overall survival with nivolumab versus docetaxel in patients with previously treated advanced non-small-cell lung cancer (NSCLC). We aimed to evaluate the long-term benefit of nivolumab and the effect of response and disease control on subsequent survival. METHODS: We pooled data from four clinical studies of nivolumab in patients with previously treated NSCLC (CheckMate 017, 057, 063, and 003) to evaluate survival outcomes. Trials of nivolumab in the second-line or later setting with at least 4 years follow-up were included. Comparisons of nivolumab versus docetaxel included all randomised patients from the phase 3 CheckMate 017 and 057 studies. We did landmark analyses by response status at 6 months to determine post-landmark survival outcomes. We excluded patients who did not have a radiographic tumour assessment at 6 months. Safety analyses included all patients who received at least one dose of nivolumab. FINDINGS: Across all four studies, 4-year overall survival with nivolumab was 14% (95% CI 11-17) for all patients (n=664), 19% (15-24) for those with at least 1% PD-L1 expression, and 11% (7-16) for those with less than 1% PD-L1 expression. In CheckMate 017 and 057, 4-year overall survival was 14% (95% CI 11-18) in patients treated with nivolumab, compared with 5% (3-7) in patients treated with docetaxel. Survival subsequent to response at 6 months on nivolumab or docetaxel was longer than after progressive disease at 6 months, with hazard ratios for overall survival of 0·18 (95% 0·12-0·27) for nivolumab and 0·43 (0·29-0·65) for docetaxel; for stable disease versus progressive disease, hazard ratios were 0·52 (0·37-0·71) for nivolumab and 0·80 (0·61-1·04) for docetaxel. Long-term data did not show any new safety signals. INTERPRETATION: Patients with advanced NSCLC treated with nivolumab achieved a greater duration of response compared with patients treated with docetaxel, which was associated with a long-term survival advantage. FUNDING: Bristol-Myers Squibb.
Authors
Antonia, SJ; Borghaei, H; Ramalingam, SS; Horn, L; De Castro Carpeño, J; Pluzanski, A; Burgio, MA; Garassino, M; Chow, LQM; Gettinger, S; Crinò, L; Planchard, D; Butts, C; Drilon, A; Wojcik-Tomaszewska, J; Otterson, GA; Agrawal, S; Li, A; Penrod, JR; Brahmer, J
MLA Citation
Antonia, Scott J., et al. “Four-year survival with nivolumab in patients with previously treated advanced non-small-cell lung cancer: a pooled analysis.Lancet Oncol, vol. 20, no. 10, Oct. 2019, pp. 1395–408. Pubmed, doi:10.1016/S1470-2045(19)30407-3.
URI
https://scholars.duke.edu/individual/pub1415124
PMID
31422028
Source
pubmed
Published In
Lancet Oncol
Volume
20
Published Date
Start Page
1395
End Page
1408
DOI
10.1016/S1470-2045(19)30407-3

Durvalumab after Chemoradiotherapy in Stage III Non-Small-Cell Lung Cancer. Reply.

Authors
MLA Citation
Antonia, Scott J. “Durvalumab after Chemoradiotherapy in Stage III Non-Small-Cell Lung Cancer. Reply.N Engl J Med, vol. 380, no. 10, Mar. 2019, p. 990. Pubmed, doi:10.1056/NEJMc1900407.
URI
https://scholars.duke.edu/individual/pub1375584
PMID
30855761
Source
pubmed
Published In
The New England Journal of Medicine
Volume
380
Published Date
Start Page
990
DOI
10.1056/NEJMc1900407